Literature DB >> 20922813

Controlling ligand surface density optimizes nanoparticle binding to ICAM-1.

Amir Fakhari1, Abdulgader Baoum, Teruna J Siahaan, Khoi Ba Le, Cory Berkland.   

Abstract

During infection, pathogens utilize surface receptors to gain entry into intracellular compartments. Multiple receptor-ligand interactions that lead to pathogen internalization have been identified and the importance of multivalent ligand binding as a means to facilitate internalization has emerged. The effect of ligand density, however, is less well known. In this study, ligand density was examined using poly(DL-lactic-co-glycolic acid) nanoparticles (PLGA NPs). A cyclic peptide, cLABL, was used as a targeting moiety, as it is a known ligand for intercellular cell adhesion molecule-1 (ICAM-1). To modulate the number of reactive sites on the surface of PLGA NPs, modified Pluronic with carboxyl groups and Pluronic with hydroxyl groups were combined in different ratios and the particle properties were examined. Utilizing a surfactant mixture directly affected the particle charge and the number of reactive sites for cLABL conjugation. The surface density of cLABL peptide increased as the relative amount of reactive Pluronic was increased. Studies using carcinomic human alveolar basal epithelial cells (A549) showed that cLABL density might be optimized to improve cellular uptake. These results complement other studies, suggesting that surface density of the targeting moiety on the NP surface should be considered to enhance the effect of ligands used for cell targeting.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20922813      PMCID: PMC4245447          DOI: 10.1002/jps.22342

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  32 in total

1.  Binding and internalization of an LFA-1-derived cyclic peptide by ICAM receptors on activated lymphocyte: a potential ligand for drug targeting to ICAM-1-expressing cells.

Authors:  H Yusuf-Makagiansar; T J Siahaan
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

2.  ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells.

Authors:  Chuda Chittasupho; Sheng-Xue Xie; Abdulgader Baoum; Tatyana Yakovleva; Teruna J Siahaan; Cory J Berkland
Journal:  Eur J Pharm Sci       Date:  2009-02-27       Impact factor: 4.384

3.  Engineering clustered ligand binding into nonviral vectors: alphavbeta3 targeting as an example.

Authors:  Quinn K T Ng; Marie K Sutton; Pan Soonsawad; Li Xing; Holland Cheng; Tatiana Segura
Journal:  Mol Ther       Date:  2009-02-24       Impact factor: 11.454

4.  Linear and cyclic LFA-1 and ICAM-1 peptides inhibit T cell adhesion and function.

Authors:  S A Tibbetts; D Seetharama Jois; T J Siahaan; S H Benedict; M A Chan
Journal:  Peptides       Date:  2000-08       Impact factor: 3.750

5.  Design of folate-linked liposomal doxorubicin to its antitumor effect in mice.

Authors:  Atsushi Yamada; Yukimi Taniguchi; Kumi Kawano; Takashi Honda; Yoshiyuki Hattori; Yoshie Maitani
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

6.  Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide.

Authors:  Ashish Garg; Alison W Tisdale; Eman Haidari; Efrosini Kokkoli
Journal:  Int J Pharm       Date:  2008-09-19       Impact factor: 5.875

7.  Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.

Authors:  Shanta Dhar; Frank X Gu; Robert Langer; Omid C Farokhzad; Stephen J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-31       Impact factor: 11.205

8.  Clustering and internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide.

Authors:  Lucie Sancey; Sancey Lucie; Elisabeth Garanger; Garanger Elisabeth; Stéphanie Foillard; Foillard Stéphanie; Guy Schoehn; Schoehn Guy; Amandine Hurbin; Hurbin Amandine; Corinne Albiges-Rizo; Albiges-Rizo Corinne; Didier Boturyn; Boturyn Didier; Catherine Souchier; Souchier Catherine; Alexeï Grichine; Grichine Alexeï; Pascal Dumy; Dumy Pascal; Jean-Luc Coll; Coll Jean-Luc
Journal:  Mol Ther       Date:  2009-03-03       Impact factor: 11.454

9.  Efalizumab binding to the LFA-1 alphaL I domain blocks ICAM-1 binding via steric hindrance.

Authors:  Sheng Li; Hao Wang; Baozhen Peng; Meilan Zhang; Daipong Zhang; Sheng Hou; Yajun Guo; Jianping Ding
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-03       Impact factor: 11.205

Review 10.  ICAM-1 signaling in endothelial cells.

Authors:  Charlotte Lawson; Sabine Wolf
Journal:  Pharmacol Rep       Date:  2009 Jan-Feb       Impact factor: 3.024

View more
  28 in total

Review 1.  Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.

Authors:  Nazila Kamaly; Zeyu Xiao; Pedro M Valencia; Aleksandar F Radovic-Moreno; Omid C Farokhzad
Journal:  Chem Soc Rev       Date:  2012-03-05       Impact factor: 54.564

Review 2.  Targeted endothelial nanomedicine for common acute pathological conditions.

Authors:  Vladimir V Shuvaev; Jacob S Brenner; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

Review 3.  Targeted Nanotherapies for the Treatment of Surgical Diseases.

Authors:  Courtney E Morgan; Molly A Wasserman; Melina R Kibbe
Journal:  Ann Surg       Date:  2016-05       Impact factor: 12.969

Review 4.  Nanocarriers for vascular delivery of anti-inflammatory agents.

Authors:  Melissa D Howard; Elizabeth D Hood; Blaine Zern; Vladimir V Shuvaev; Tilo Grosser; Vladimir R Muzykantov
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

5.  Modulating Macrophage Polarization through CCR2 Inhibition and Multivalent Engagement.

Authors:  Michael B Deci; Scott W Ferguson; Sydney L Scatigno; Juliane Nguyen
Journal:  Mol Pharm       Date:  2018-06-04       Impact factor: 4.939

Review 6.  Applications of nanomaterials as vaccine adjuvants.

Authors:  Motao Zhu; Rongfu Wang; Guangjun Nie
Journal:  Hum Vaccin Immunother       Date:  2014-11-17       Impact factor: 3.452

7.  Antioxidant protection by PECAM-targeted delivery of a novel NADPH-oxidase inhibitor to the endothelium in vitro and in vivo.

Authors:  Elizabeth D Hood; Colin F Greineder; Chandra Dodia; Jingyan Han; Clementina Mesaros; Vladimir V Shuvaev; Ian A Blair; Aron B Fisher; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2012-09-06       Impact factor: 9.776

8.  Optimization of cell receptor-specific targeting through multivalent surface decoration of polymeric nanocarriers.

Authors:  Suzanne M D'Addio; Steven Baldassano; Lei Shi; Lila Cheung; Douglas H Adamson; Matthew Bruzek; John E Anthony; Debra L Laskin; Patrick J Sinko; Robert K Prud'homme
Journal:  J Control Release       Date:  2013-02-16       Impact factor: 9.776

9.  Targeted PRINT Hydrogels: The Role of Nanoparticle Size and Ligand Density on Cell Association, Biodistribution, and Tumor Accumulation.

Authors:  Kevin G Reuter; Jillian L Perry; Dongwook Kim; J Christopher Luft; Rihe Liu; Joseph M DeSimone
Journal:  Nano Lett       Date:  2015-09-30       Impact factor: 11.189

10.  Reduction of nanoparticle avidity enhances the selectivity of vascular targeting and PET detection of pulmonary inflammation.

Authors:  Blaine J Zern; Ann-Marie Chacko; Jin Liu; Colin F Greineder; Eric R Blankemeyer; Ravi Radhakrishnan; Vladimir Muzykantov
Journal:  ACS Nano       Date:  2013-02-08       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.